CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Savara Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Savara Inc
6836 BEE CAVE ROAD
BUILDING 3, SUITE 201
Phone: (512) 851-13796p:512 851-13796 AUSTIN, TX  78746  United States Ticker: SVRASVRA
Business Summary
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer MatthewPauls 53 12/8/2020 4/1/2017
Chief Financial and Administrative Officer, Secretary David L.Lowrance 56 12/13/2022 11/1/2016
Chief Operating Officer Robert M.Lutz 55 2/13/2023 2/13/2023
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Serendex Pharmaceuticals A/S Slotsmarken 17, 2. tv HOERSHOLM Denmark
Aires Pharmaceuticals, Inc. 4365 Executive Drive San Diego CA United States

Business Names
Business Name
Aires Pharmaceuticals, Inc.
AVRX
BKYS
9 additional Business Names available in full report.

General Information
Number of Employees: 37 (As of 3/7/2024)
Outstanding Shares: 171,618,944 (As of 11/8/2024)
Shareholders: 103
Stock Exchange: NASD
Federal Tax Id: 841318182
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024